Melane Sampson, Author at BioTuesdays

Developments

EC grants marketing authorization for Autolus’ AUCATZYL for rr/B-ALL

Autolus Therapeutics (NASDAQ: AUTL) has announced that the European Commission (EC) has granted marketing authorization for AUCATZYL for the treatment of adult patients aged 26 and over with relapsed or refractory B...

July 21, 2025

Developments

USPTO grants Autonomix patent for smart torquer device

Autonomix Medical (NASDAQ: AMIX) has announced that the United States Patent and Trademark Office (USPTO) has issued a patent for its smart torquer device. The device is designed to enhance the manipulation of elongated...

July 21, 2025

Developments

Cuprina names Dr. Ronald Sherman as medical and scientific director; secures FDA-approved medical maggot license

Cuprina Holdings (NASDAQ: CUPR) has announced the appointment of Dr. Ronald Sherman, a leading innovator in maggot debridement therapy (MDT), as medical and scientific director, effective September 2025—securing the...

July 21, 2025

Developments

Knight files NDS for CREXONT in Canada

Knight Therapeutics (TSX: GUD) has announced that its new drug submission (NDS) for CREXONT—a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease—has...

July 18, 2025

Executive Moves

Bryan Baum joins Senti’s BOD

Senti Bio (NASDAQ: SNTI) has announced the appointment of entrepreneurial leader and investor Bryan Baum to its board of directors (BOD). Mr. Baum is the co-founder and managing partner of K5 Global. His portfolio...

July 18, 2025

Developments

Ekso Bionics launches virtual eksoUniversity to support CE for PTs and PTAs

Ekso Bionics (NASDAQ: EKSO) has announced the launch of eksoUniversity, a new platform providing continuing education (CE) courses to physical therapists (PTs) and physical therapy assistants (PTAs) across the U.S. Most...

July 18, 2025

Developments

Cell One Partners’ video series: Dr. Stephen Chang reflects on 40 years of innovation in cell and gene therapy

In the latest episode of consulting company Cell One Partners’ video series—Cell One Insights—on cell and gene therapy, Stephen Chang, PhD—a human geneticist and partner at Cell One Partners—shares insights from his 40...

July 15, 2025

Executive Moves

Iovance appoints Corleen Roche as CFO

Iovance Biotherapeutics (NASDAQ: IOVA) has announced the appointment of Corleen Roche as chief financial officer (CFO), effective August 6, 2025. Ms. Roche brings three decades of biotech and life sciences industry...

July 15, 2025

Developments

BiomX doses first patient in Phase 2b trial of BX004 in CF

BiomX (NYSE: PHGE) has announced the initiation of patient dosing in its Phase 2b trial evaluating BX004 for the treatment of cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas...

July 15, 2025

Feature

EsoBiotec unlocking new possibilities for oncology and autoimmune disease by empowering cells in vivo

Closely held EsoBiotec is transforming cell therapy by engineering immune cells directly within a patient’s body, enabling the immune system to attack disease—potentially delivering cell therapy to patients in minutes...

July 15, 2025

Author - Melane Sampson

EC grants marketing authorization for Autolus’ AUCATZYL for rr/B-ALL

USPTO grants Autonomix patent for smart torquer device

Cuprina names Dr. Ronald Sherman as medical and scientific director; secures FDA-approved medical maggot license

Knight files NDS for CREXONT in Canada

Bryan Baum joins Senti’s BOD

Ekso Bionics launches virtual eksoUniversity to support CE for PTs and PTAs

Cell One Partners’ video series: Dr. Stephen Chang reflects on 40 years of innovation in cell and gene therapy

Iovance appoints Corleen Roche as CFO

BiomX doses first patient in Phase 2b trial of BX004 in CF

EsoBiotec unlocking new possibilities for oncology and autoimmune disease by empowering cells in vivo

Subscribe